Get the Stockscreener App
0.69
2.99%
0.02
After Hours:
.69
Vaccinex Inc stock is traded at $0.69, with a volume of 13,983.
It is up +2.99% in the last 24 hours and down -20.46% over the past month.
See More
Previous Close:
$0.67
Open:
$0.561516
24h Volume:
13,983
Relative Volume:
23.43
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-22.01M
P/E Ratio:
-0.00808
EPS:
-85.4
Net Cash Flow:
$-18.31M
1W Performance:
+2.99%
1M Performance:
-20.46%
6M Performance:
-2.82%
1Y Performance:
-88.61%
1-Day Range:
$0.5615
$0.70
1-Week Range:
$0.5615
$0.70
52-Week Range:
$0.46
$1.13
Vaccinex Inc Stock (VCNX) Company Profile
Compare VCNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VCNX
Vaccinex Inc
|
0.69 | 0 | 0 | -22.01M | -18.31M | -85.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.38 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.71 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
396.04 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
847.05 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.55 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vaccinex Inc Stock (VCNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-23-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-04-18 | Initiated | Ladenburg Thalmann | Buy |
Vaccinex Inc Stock (VCNX) Latest News
Best Biotech Penny Stocks Right Now • Updated Daily - Benzinga
NeurAxis, Inc. (NRXS) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
AIM ImmunoTech Inc. (AIMI) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Revenue per share of Vaccinex, Inc. – OTC:VCNX - TradingView
Vaccinex (NASDAQ:VCNX) Trading 4.2% Higher – Time to Buy? - Defense World
Vaccinex (NASDAQ:VCNX) Stock Price Down 5.7% – Time to Sell? - Defense World
Contrasting Vaccinex (NASDAQ:VCNX) & Palatin Technologies (PINK:PTNT) - Defense World
NF-κB Inhibitors Market to Witness Accelerated Expansion Across the 7MM through 2034 | DelveInsight - PR Newswire UK
What sets apart Novavax option from other COVID-19 vaccines - American Medical Association
Vaccinex, Inc. (NASDAQ:VCNX) Sees Significant Growth in Short Interest - Defense World
GLP-1 Agonists Market to Show Impressive Growth at a CAGR of 10.8% During the Forecast Period (2025-2034) | DelveInsight - PR Newswire
Senators from both parties grilled RFK Jr. on vaccines and more - NPR
Vaccine Development - Gates Foundation
TR | OpenAI4o Maintains Vaccinex(VCNX.US) With Hold Rating, Cuts Target Price to $0.5 - 富途牛牛
Head to Head Survey: Aerovate Therapeutics (NASDAQ:AVTE) vs. Vaccinex (NASDAQ:VCNX) - Defense World
Vaccinex (NASDAQ:VCNX) Trading 26.3% Higher – Here’s Why - Defense World
Cannabinoid Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - India Shorts
Cannabinoid Clinical Trial Pipeline Gains Momentum: 50+ - GlobeNewswire
Progressive Supranuclear Palsy Market on Upward Trajectory During the Forecast Period (2025-2034) with Emerging Immunotherapies | DelveInsight - The Malaysian Reserve
Huntington’s Disease Market to Expand Significantly by 2034, States DelveInsight Report | Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics - Barchart.com
Huntington's Disease Market To Expand Significantly By 2034, States Delveinsight Report Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics - Menafn
Highest-Paid CEOs - AFL-CIO
Cannabinoid Agonist Clinical Trial Pipeline Appears Robust - GlobeNewswire
Alzheimer’s Therapeutics Market on Upward Trajectory Across - GlobeNewswire
Vaccinex (NASDAQ:VCNX) Shares Down 2.7% – Time to Sell? - Defense World
Alzheimer's Disease Clinical Trials 2025: EMA, PDMA, FDA - openPR.com
Vaccinex to Report Promising New Clinical Results of - GlobeNewswire
Vaccinex to Report Promising New Clinical Data Revealing - GlobeNewswire
Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On - Citeline News & Insights
Vaccinex plans Nasdaq exit as Alzheimer market pressure grows - Pharmaceutical Technology
Can Vaccinex Survive After Nasdaq Exit? Key Details on Company's Future Strategy - Stock Titan
RFK Jr. says he's resigned from anti-vaccine nonprofit as he seeks nation's top health official job - AP News
Louisiana forbids public health workers from promoting COVID, flu and mpox shots : ShotsHealth News - NPR
VCNX Stock Price and Chart — OTC:VCNX - TradingView
United States shares lower at close of trade; Dow Jones Industrial Average down 0.61% - Investing.com India
Vaccinex Faces Nasdaq Delisting Amid Financial Struggles; Shares Drop 62% - Yahoo Finance
School Vaccine Mandates - Britannica
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update - Yahoo Finance
75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - PR Newswire
Vaccinex inks multiple antibody discovery deals using ActivMAb By Investing.com - Investing.com UK
Vaccinex reports progress in Alzheimer's treatment study - Investing.com
Vaccinex Stock Spikes On Promising Data On Alzheimer’s Drug Study: Retail Sentiment Brightens - Stocktwits
Vaccinex faces potential Nasdaq delisting over equity shortfall By Investing.com - Investing.com UK
Vaccinex stock hits 52-week low at $2.98 amid market challenges - Investing.com India
Vaccinex exercises warrants for proceeds of $6.2M - Seeking Alpha
Vaccinex Director Chrystyna Bedrij Stecyk Abruptly Resigns - TipRanks
Nanoplatform Based Intranasal Vaccines: Current Progress and Clinical Challenges - ACS Publications
VCNX Stock Earnings: Vaccinex Reported Results for Q2 2024 - TradingView — Track All Markets
StockWatch: Cognition Stays the Course as Shares Plunge on Alzheimer’s Data - Genetic Engineering and Biotechnology News
Alzheimer’s drug development roundup – July 2024 - European Pharmaceutical Review
Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease - Stock Titan
Vaccinex Inc Stock (VCNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.31%
0.33%
Cap:
|
Volume (24h):